



Preliminary program updated 21.10.24

THURSDAY, MARCH 20th

THURSDAY, MARCH 20 th		
08:00-09:40	Neuroimmunology	HALL A
Chairs:		
08:00-08:50	Is MOGAD due to anti-MOG Abs?	
	<i>Capsule:</i>	
08:00-08:10	Moderator: Brian Weinshenker , USA Introduction and Pre-Debate Voting	
08:10-08:25	Yes: Patrick Waters , UK	
08:25-08:40	No: Thomas Berger , Austria	
08:40-08:50	Discussion, Rebuttals and Post-Debate Voting	
08:50-09:40	Is testing for alternative antibodies (e.g. anti-LRP4) indicated in patients with acquired myasthenia gravis who are double seronegative (negative anti-AchR and negative anti-MUSK)	
	<i>Capsule:</i>	
08:50-09:00	Moderator: Introduction and Pre-Debate Voting	
09:00-09:15	Yes: Hakan Cetin , Austria	
09:15-09:30	No: Patrick Waters , UK	
09:30-09:40	Discussion, Rebuttals and Post-Debate Voting	
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-10:50	Opening Ceremony	Plenary Hall
10:50-11:50	Plenary Session	Plenary Hall
11:50-12:50	Industry Sponsored Symposium	Plenary Hall
12:50-13:50	Lunch Break, Exhibition & ePosters Visits	



THURSDAY, MARCH 20th , 2025

13:50-15:30		Neuroimmunology (continued)	HALL A
13:50-14:40	All patients with PML should be treated with pembrolizumab		
	<i>Capsule:</i>		
13:50-14:00	Moderator: TBA Introduction and Pre-Debate Voting		
14:00-14:15	Yes:		
14:15-14:30	No: Michel Toledano , USA		
14:30-14:40	Discussion, Rebuttals and Post-Debate Voting		
14:40-15:30	Is CAR-T cell therapy appropriate for development fro NMOSD?		
	<i>Capsule:</i>		
14:40-14:50	Moderator: TBA Introduction and Pre-Debate Voting		
14:50-15:05	Yes: Brian Weinschenker , USA		
15:05-15:20	No: Petra Nytrova , Czech Republic		
15:20-15:30	Discussion, Rebuttals and Post-Debate Voting		
15:30-16:00	Coffee Break, Exhibition & ePosters Visits		
16:00-17:40	Neuroimmunology (continued)		
16:00-16:50	Can primary CNS vasculitis be diagnosed without biopsy?		
	<i>Capsule:</i>		
16:00-16:10	Moderator: Michel Toledano , USA Introduction and Pre-Debate Voting		
16:10-16:25	Yes: Sarlota Mesaros , Serbia		
16:25-16:40	No:		
16:40-16:50	Discussion, Rebuttals and Post-Debate Voting		



THURSDAY, MARCH 20 th , 2025		HALL A
	Neuroimmunology (continued)	
16:50-17:40	Narcolepsy is an autoimmune disorder	
16:50-17:00	Moderator: Ivana Rosenzweig, UK Introduction and Pre-Debate Voting	
17:00-17:15	Yes: Roland Liblau, France	
17:15-17:30	No: Mehdi Tafti, Switzerland	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	
17:40	Networking Reception	



THURSDAY, MARCH 20th , 2025

08:00-09:40	Alzheimer's Disease (AD) & Dementia	HALL B
Chairs:	TBA	
08:00-08:50	Alzheimer's Association debate: Individuals with atypical AD should be included in clinical trials	
	<i>Capsule:</i>	
08:00-08:10	Moderator: Rik Ossenkoppele , Netherlands Introduction and Pre-Debate Voting	
08:10-08:25	Yes: Keir Young , UK	
08:25-08:40	No: Rosaleena Mohanty , Sweden	
08:40-08:50	Discussion, Rebuttals and Post-Debate Voting	
08:50-09:40	Are the new anti-amyloid drugs cost-effective?	
	<i>Capsule:</i>	
08:50-09:00	Moderator: TBA Introduction and Pre-Debate Voting	
09:00-09:15	Yes: Jakub Hlavka , Czech Republic	
09:15-09:30	No:	
09:30-09:40	Discussion, Rebuttals and Post-Debate Voting	
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-10:50	Opening Ceremony	Plenary Hall
10:50-11:50	Plenary Session	Plenary Hall
11:50-12:50	Industry Sponsored Symposium	Plenary Hall
12:50-13:50	Lunch Break, Exhibition & ePosters Visits	
13:50-15:30	Alzheimer's Disease (AD) & Dementia (continued)	HALL B
13:50-14:40	Should MCI patients be immunized against zoster?	
	<i>Capsule:</i>	
13:50-14:00	Moderator: Introduction and Pre-Debate Voting	
14:00-14:15	Yes: Dong Hui Lim , Korea	
14:15-14:30	No:	
14:30-14:40	Discussion, Rebuttals and Post-Debate Voting	



THURSDAY, MARCH 20 th , 2025		
	Alzheimer's Disease (AD) & Dementia (continued)	HALL B
14:40-15:30	Is AD a disease?	
	<i>Capsule:</i> The definition of AD has changed several times over the years and still lacks an agreed one. Lacking understanding of the causes and mechanisms of the condition, it is still arguable whether it should be considered a disease or a syndrome	
14:40-14:50	Moderator: Michael Okun , USA Introduction and Pre-Debate Voting	
14:50-15:05	Yes: Colin L. Masters , Australia	
15:05-15:20	No: Amos Korczyn , Israel	
15:20-15:30	Discussion, Rebuttals and Post-Debate Voting	
15:30-16:00	Coffee Break, Exhibition & ePosters Visits	
16:00-17:40	Alzheimer's Disease (AD) & Dementia (continued)	HALL B
16:00-16:50	Monoclonal antibodies or natural products for prevention of dementia?	
	<i>Capsule:</i>	
16:00-16:10	Moderator: Robert Perneczky , Germany Introduction and Pre-Debate Voting	
16:10-16:25	Natural products: Magda Tsolaki , Greece	
16:25-16:40	Monoclonal antibodies: Jakub Hort , Czech Republic	
16:40-16:50	Discussion, Rebuttals and Post-Debate Voting	
16:50-17:40	Do lifestyle factors protect against dementia by affecting amyloid metabolism?	
	<i>Capsule:</i>	
16:50-17:00	Moderator: Robert Perneczky , Germany Introduction and Pre-Debate Voting	
17:00-17:15	Yes: Laura Bonanni , Italy	
17:15-17:30	No: Miia Kivipelto , Sweden	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	
17:40	Networking Reception	



THURSDAY, MARCH 20th , 2025

08:00-09:40	Parkinson's Disease (PD) I	HALL C
Chairs:	TBA	
08:00-08:50	Are we ready to classify PD based on biological information?	
	<i>Capsule:</i>	
08:00-08:10	Moderator: Michael Okun, USA Introduction and Pre-Debate Voting	
08:10-08:25	Yes: Tiago Outeiro , Germany	
08:25-08:40	No: Angelo Antonini, Italy	
08:40-08:50	Discussion, Rebuttals and Post-Debate Voting	
08:50-09:40	The first treatment of RLS should be dopamine agonists vs gabapentin and pregabalin	
	<i>Capsule:</i>	
08:50-09:00	Moderator: Karel Sonka , Czech Republic Introduction and Pre-Debate Voting	
09:00-09:15	Dopamine agonists: Vladmira Vuletic , Croatia	
09:15-09:30	Gabapentin / pregabalin: Jarosław Slawek , Poland	
09:30-09:40	Discussion, Rebuttals and Post-Debate Voting	
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-10:50	Opening Ceremony	Plenary Hall
10:50-11:50	Plenary Session	Plenary Hall
11:50-12:50	Industry Sponsored Symposium	Plenary Hall
12:50-13:50	Lunch Break, Exhibition & ePosters Visits	
13:50-17:40	Parkinson's Disease (PD) I (continued)	HALL C
13:50-14:40	The MRI will replace molecular imaging to support the diagnosis of PD	
	<i>Capsule:</i>	
13:50-14:00	Moderator: Heinz Reichmann , Germany Introduction and Pre-Debate Voting	
14:00-14:15	Yes: Irena Rektorova , Czech Republic	
14:15-14:30	No: Nicola Pavese , UK	
14:30-14:40	Discussion, Rebuttals and Post-Debate Voting	



THURSDAY, MARCH 20th , 2025

Parkinson's Disease (PD) I (continued)		HALL C
14:40-15:30	GLP-1 agonists are disease modifying for PD	
	<i>Capsule:</i>	
14:40-14:50	Moderator: Michael Okun , USA Introduction and Pre-Debate Voting	
14:50:15:05	Yes: Sharon Hassin-Baer , Israel	
15:05:15:20	No:	
15:20-15:30	Discussion, Rebuttals and Post-Debate Voting	
15:30-16:00	Coffee Break, Exhibition & ePosters Visits	
Parkinson's Disease (PD) I (continued)		HALL C
16:00-16:50	Essential tremor plus is a clinically useful concept	
	<i>Capsule:</i>	
16:00-16:10	Moderator: Sharon Hassin-Baer , Israel Introduction and Pre-Debate Voting	
16:10-16:25	Yes: Matej Skorvanek , Slovakia	
16:25-16:40	No: Evzen Ruzicka , Czech Republic	
16:40-16:50	Discussion, Rebuttals and Post-Debate Voting	
16:50-17:40	Focused ultrasound thalamotomy becomes the first choice treatment for medically refractory essential tremor	
	<i>Capsule:</i>	
16:50-17:00	Moderator: Evzen Ruzicka , Czech Republic Introduction and Pre-Debate Voting	
17:00-17:15	Yes: Ilana Schlesinger , Israel	
17:15-17:30	No: Michael Okun , USA	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	



FRIDAY, MARCH 21 ST , 2025		
08:00-09:40	Multiple Sclerosis (MS)	HALL A
Chairs:	TBA	
08:00-08:50	European Charcot Foundation Symposium: Assessment of treatment response in progressive MS	
	<i>Capsule:</i>	
	Moderator: Hans-Peter Hartung , Germany Introduction and Pre-Debate Voting	
	Clinical measures: Ludwig Kappos , Switzerland	
	Neuroimaging: Bruno Stankoff , France	
	Functional tests: Letizia Leocani , Italy	
08:40-08:50	Discussion, Rebuttals and Post-Debate Voting	
08:50-09:40	Epstein - Barr virus is a therapeutic and preventive target in MS	
	<i>Capsule:</i>	
08:50-09:00	Moderator: Jacek Losy , Poland Introduction and Pre-Debate Voting	
09:00-09:15	Yes: Gavin Giovannoni , UK	
09:15-09:30	No: Giancarlo Comi , Italy	
09:30-09:40	Discussion, Rebuttals and Post-Debate Voting	
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-11:10	Plenary Session	Plenary Hall
11:10-12:10	Industry Sponsored Symposium	Plenary Hall
12:10-13:10	Lunch Break, Exhibition & ePosters Visits	



FRIDAY, MARCH 21ST, 2025

13:10-14:50	Multiple Sclerosis (continued)	HALL A
13:10-14:00	Does Prodromal MS exists?	
	<i>Capsule:</i>	
	Moderator: Gavin Giovannoni , UK Introduction and Pre-Debate Voting	
	Yes: Hans-Peter Hartung , Germany	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
14:00-14:50	All patients with RIS should be treated with a DMT	
14:00-14:10	<i>Capsule:</i>	
14:10:14:25	Moderator: Giancarlo Comi , Italy Introduction and Pre-Debate Voting	
14:25-14:40	Yes: Olaf Stuve, USA	
14:40-14:50	No: Klaus Schmierer , UK	
	Discussion, Rebuttals and Post-Debate Voting	
14:50-15:20	Coffee Break, Exhibition & ePosters Visits	
15:20-17:00	Multiple Sclerosis (continued)	HALL A
15:20-16:10	Digital technology should replace neurological examination	
	<i>Capsule:</i>	
	Moderator: Introduction and Pre-Debate Voting	
	Yes: Letizia Leocani , Italy	
	No: Tjalf Ziemssen , Germany	
	Discussion, Rebuttals and Post-Debate Voting	



FRIDAY, MARCH 21 ST , 2025		HALL A
	Multiple Sclerosis (continued)	
16:10-17:00	PET scanning should be a regular part of the follow up routine in patients with progressive MS	
	<i>Capsule:</i>	
	Moderator: Letizia Leocani , Italy Introduction and Pre-Debate Voting	
	Yes:	
	No: Eva Havrdova , Czech Republic	
	Discussion, Rebuttals and Post-Debate Voting	
17:00-18:00	e-Posters Guided Tour	



FRIDAY, MARCH 21 ST , 2025		
08:00-09:40	Stroke	HALL B
Chairs:	TBA	
08:00-08:50	POINT(S) and COMPASS(ES). Should stroke physicians use a combination of aspirin and low dose Rivaroxaban to reduce risk of recurrent in high risk people with large artery disease?	
	<i>Capsule:</i> The COMPASS trial demonstrated that people with stable atherosclerotic vascular disease who were treated with a combination of low dose rivaroxaban and aspirin had better cardiovascular outcomes but more bleeding than people treated with aspirin alone. Most of the participants were enrolled into the study due to a history of myocardial infarction or peripheral vascular disease and people with a recent stroke were excluded. However, we see many patients who suffer stroke despite being treated with antiplatelets. Is this a viable treatment option for people with stroke due to large artery disease, or would single or dual antiplatelet therapy be preferable?	
08:00-08:10	Moderator: Natan Bornstein , Israel Introduction and Pre-Debate Voting	
08:10-08:25	Yes: Robert Gabor Kiss , Hungary	
08:25-08:40	No: Jesse Dawson , Scotland	
08:40-08:50	Discussion, Rebuttals and Post-Debate Voting	
08:50-09:40	Time to get the gout drugs out? Colchicine for prevention of stroke. Are you CONVINCED?	
	<i>Capsule:</i> The use of colchicine to prevent cardiovascular events in people with atherosclerotic coronary heart disease was recently approved by the FDA. At least some of the benefit observed is due to a reduction in stroke. The CONVINCENCE and CHANCE-3 trials recently assessed this in people with recent ischaemic stroke. Should we now be using this in people with ischaemic stroke?	
08:50-09:00	Moderator: Natan Bornstein , Israel Introduction and Pre-Debate Voting	
09:00-09:15	Yes: Ashfaq Shuaib , Canada	
09:15-09:30	No: Vida Demarin , Croatia	
09:30-09:40	Discussion, Rebuttals and Post-Debate Voting	
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-11:10	Plenary Session	Plenary Hall
11:10-12:10	Industry Sponsored Symposium	Plenary Hall
12:10-13:10	Lunch Break, Exhibition & ePosters Visits	



FRIDAY, MARCH 21ST, 2025

13:10-14:50		Stroke (continued)	HALL B
13:10-14:00	Should we offer EVT to patients with acute stroke and pre-stroke mRS of 3 or more?		
	<p><i>Capsule:</i> Randomized trials with endovascular treatment (EVT) of acute stroke have excluded patients with pre-stroke modified Rankin scale (mRS) of more than "2". Despite lacking trial data, patients with higher mRS are offered EVT. Does the lack of trial data require additional studies in high mRS patients with LVO and acute stroke? Is the data from current trials sufficient to offer treatment regardless of the pre-stroke mRS?</p>		
	<p>Moderator: Roni Eichel, Israel Introduction and Pre-Debate Voting</p>		
	<p>Yes: Ashfaq Shuaib, Canada</p>		
	<p>No: Robert Mikulik, Czech Republic</p>		
	<p>Discussion, Rebuttals and Post-Debate Voting</p>		
14:00-14:50	CTP is rarely needed for decision making in patients with ischemic stroke		
	<p><i>Capsule:</i> Reason is that you do not know if there is large core until you have CTP. And CTP can offer other benefits beyond indication of MT</p>		
	<p>Moderator: Robert Mikulik, Czech Republic Introduction and Pre-Debate Voting</p>		
	<p>Yes: Roni Eichel, Israel</p>		
	<p>No: Ashfaq Shuaib, Canada</p>		
	<p>Discussion, Rebuttals and Post-Debate Voting</p>		
14:50-15:20		Coffee Break, Exhibition & ePosters Visits	
15:20-17:00		Stroke (continued)	HALL B
15:20-16:10	There are sufficient data to use Andexanat alpha in people with ICH associated with factor X inhibitor use		
	<p><i>Capsule:</i> In people with ICH associated with the use of FXa inhibitors, treatment with andexanet alfa reduces anti-FXa activity and has good hemostatic efficacy. There are also reports that it is associated with lower mortality and better clinical outcomes. However, there may be an increased risk of thrombotic events so the risk benefit ratio may be hard to define. Are there sufficient data to support routine use?</p>		
	<p>Moderator: Jesse Dawson, Scotland Introduction and Pre-Debate Voting</p>		
	<p>Yes:</p>		
	<p>No:</p>		
	<p>Discussion, Rebuttals and Post-Debate Voting</p>		



FRIDAY, MARCH 21 ST , 2025		
	Stroke (continued)	HALL B
16:10-17:00	Is tele-rehabilitation ready for implementation in a daily practice?	
	<i>Capsule:</i>	
	Moderator: Dafin Muresanu , Romania Introduction and Pre-Debate Voting	
	Yes:	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
17:00-18:00	e-Posters Guided Tour	

FRIDAY, MARCH 21 ST , 2025		
08:00-09:40	Parkinson's Disease (PD) II	HALL C
09:40-10:10	Coffee Break, Exhibition & ePosters Visits	
10:10-11:10	Plenary Session	Plenary Hall
11:10-12:10	Industry Sponsored Symposium	Plenary Hall
12:10-13:10	Lunch Break, Exhibition & ePosters Visits	
13:10-14:50	Parkinson's Disease (PD) II (continued)	HALL C
14:50-15:20	Coffee Break, Exhibition & ePosters Visits	
15:20-17:00	Parkinson's Disease (PD) II continued)	HALL C
17:00-18:00	e-Posters Guided Tour	



SATURDAY, MARCH 22ND, 2025

07:30-08:30	e-Posters Guided Tour	
08:30-10:10	Sleep	HALL A
Chairs:	TBA	
08:30-09:20	Sleep enhances brain clearance	
	<i>Capsule:</i>	
	Moderator: Claudio Bassetti , Switzerland Introduction and Pre-Debate Voting	
	Yes: Maiken Nedergaard , Denmark/USA	
	No: Karel Sonka , Czech Republic	
	Discussion, Rebuttals and Post-Debate Voting	
09:20-10:10	Is sleep assessment essential in general neurology practice?	
	<i>Capsule:</i>	
	Moderator: Ivana Rosenzweig , UK Introduction and Pre-Debate Voting	
	Yes: Claudio Bassetti , Switzerland	
	No: Birgit Hoegl , Austria	
	Discussion, Rebuttals and Post-Debate Voting	
10:10-10:40	Coffee Break, Exhibition & ePosters Visits	
10:40-11:40	Plenary Session	Plenary Hall
11:40-12:40	Industry Sponsored Symposium	Plenary Hall
12:40-13:40	Lunch Break, Exhibition & ePosters Visits	



SATURDAY, MARCH 22ND, 2025

13:40-15:20 ALS		HALL A
Chairs	TBA	
13:40-14:30	Physiological stress, as derived from smoking and extreme exercise as a risk factor for ALS	
	<i>Capsule: Extreme physical activity and smoking have been linked to an increased risk of developing Amyotrophic Lateral Sclerosis (ALS). Physiological stress, when ongoing, extreme or uncontrolled, may thus result in neurodegeneration, particularly with ALS</i>	
	Moderator: Pamela Shaw , UK Introduction and Pre-Debate Voting	
	Yes: Amir Dorj , Israel	
	No: Osman Sinanovic , Bosnia and Herzegovina	
	Discussion, Rebuttals and Post-Debate Voting	
14:30-15:20	For neuroprotection in ALS - targetted therapies represent a better approach than therapeutic cocktails	
	<i>Capsule:</i>	
	Moderator: TBA Introduction and Pre-Debate Voting	
	Yes: Pamela Shaw , UK	
	No: Albert Ludolph , Germany	
	Discussion, Rebuttals and Post-Debate Voting	
15:20-15:50	Coffee Break, Exhibition & ePosters Visits	
15:50-17:30 Neurodegenerative Diseases		HALL A
Chairs	TBA	
15:50-16:40	The age-dependent decrease of brain clearing mechanisms is responsible for late-onset neurodegenerative diseases	
	<i>Capsule:</i>	
	Moderator: Vladimira Vuletic , Croatia Introduction and Pre-Debate Voting	
	Yes: Bogdan Popescu , Romania	
	No: Laura Bonanni , Italy	
	Discussion, Rebuttals and Post-Debate Voting	



SATURDAY, MARCH 22ND, 2025

Neurodegenerative Diseases (continued)		HALL A
16:40-17:30	Palliative care should be discussed with people with progressive neurological disease early in the disease progression	
	<i>Capsule:</i>	
	Moderator: TBA	
	Introduction and Pre-Debate Voting	
	Yes: Robert Rusina , Czech Republic	
	No: Vladimira Vuletic , Croatia	
	Discussion, Rebuttals and Post-Debate Voting	
17:50	Closing ceremony	



SATURDAY, MARCH 22ND, 2025

07:30-08:30	e-Posters Guided Tour	
08:30-10:10	Epilepsy	HALL B
Chairs		
08:30-09:20	Are the newest drugs for epilepsy, cenobamate and fenfluramine better than the older drugs?	
	<i>Capsule: Drugs introduced to treat epilepsy in the 1990's and 2000's did not produce seizure freedom at greater rates than older drugs. Are the newest drugs better?</i>	
	Moderator: TBA Introduction and Pre-Debate Voting	
	Yes: Michael Sperling , USA	
	No: Ivan Rektor , Czech Republic	
	Discussion, Rebuttals and Post-Debate Voting	
09:20-10:10	Should we still use therapeutic drug monitoring when treating our patients with epilepsy?	
	<i>Capsule: Does therapeutic drug monitoring really lead to better outcomes and seizure control or is management using clinical parameters adequate?</i>	
	Moderator: TBA Introduction and Pre-Debate Voting	
	Yes: Ilan Blatt , Israel	
	No: Manjari Tripathi , India	
	Discussion, Rebuttals and Post-Debate Voting	
10:10-10:40	Coffee Break, Exhibition & ePosters Visits	
10:40-11:40	Plenary Session	Plenary Hall
11:40-12:40	Industry Sponsored Symposium	Plenary Hall
12:40-13:40	Lunch Break, Exhibition & ePosters Visits	
13:40-15:20	Epilepsy (continued)	HALL B
13:40-14:30	Should we use add-on therapy or substitution therapy for epilepsy when the first drug does not work?	
	<i>Capsule: For most patients, is add-on and substitution of a new drug best when the first drug fails to control seizures? What is the evidence?</i>	
	Moderator: TBA Introduction and Pre-Debate Voting	
	Add on: Alla Guekht , Russia	
	Substitution: Andreas Schulze-Bonhage , Germany	



	Discussion, Rebuttals and Post-Debate Voting	
14:30-15:20	Case studies. Michael Sperling , USA	
14:30-15:10	Case Studies	
15:10-15:20	Discussion	
15:20-15:50	Coffee Break, Exhibition & ePosters Visits	
15:50-17:30	Epilepsy (continued)	HALL B
15:50-16:40	Should we be targeting nuclei for deep brain stimulation other than the anterior thalamic nucleus for drug-resistant focal epilepsy?	
	<i>Capsule: Stimulation of the anterior nucleus of the thalamus has been shown to reduce seizure frequency in a randomized controlled trial. Multiple subocortical thalamic nuclei, including pulvinar and centromedian, are being now stimulated instead in clinical practice. Is this justified?</i>	
	Moderator: Firas Fahoum , Israel Introduction and Pre-Debate Voting	
	Yes: Ivan Rektor , Czech Republic	
	No: Martin Holtkamp , Germany	
	Discussion, Rebuttals and Post-Debate Voting	
16:40-17:30	Should we treat seizures that we see in the subclinical electrographic seizures in EEG in status epilepticus when clinical seizures have stopped?	
	<i>Capsule: It is common to see electrographic seizures after cessation of status epilepticus in the intensive care unit. Can we justify treating these with continued aggressive therapy? Is there evidence to support improved outcome with or without treatment?</i>	
	Moderator: Vladimir Komarek , Czech Republic Introduction and Pre-Debate Voting	
	Yes: Ilan Blatt , Israel	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
17:40	Closing ceremony	



SATURDAY, MARCH 22ND, 2025

07:30-08:30	e-Posters Guided Tour	
08:30-10:10	Headache	HALL C
Chairs		
08:30-09:20	anti-CGRP therapies should be first line for migraine prevention	
	<i>Capsule:</i>	
	Moderator: Tomas Nezadal , Czech Republic	
	Introduction and Pre-Debate Voting	
	Yes: Antoinette Maassen van den Brink , The Netherlands	
	No: Gisela Terwindt , The Netherlands	
	Discussion, Rebuttals and Post-Debate Voting	
09:20-10:10	There is a need for other botulinum neurotoxins other than Botox for prevention of chronic migraine	
	<i>Capsule:</i>	
	Moderator:	
	Introduction and Pre-Debate Voting	
	Yes: Peter McAllister , USA	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
10:10-10:40	Coffee Break, Exhibition & ePosters Visits	
10:40-11:40	Plenary Session	Plenary Hall
11:40-12:40	Industry Sponsored Symposium	Plenary Hall
12:40-13:40	Lunch Break, Exhibition & ePosters Visits	
13:40-15:20	Headache (continued)	HALL C
13:40-14:30	Psychedelics such as psilocybin and ketamine are reasonable treatment choices for both migraine and cluster headache	
	<i>Capsule:</i>	
	Moderator:	
	Introduction and Pre-Debate Voting	
	Yes: Peter McAllister , USA	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	



SATURDAY, MARCH 22ND, 2025

SATURDAY, MARCH 22 ND , 2025		HALL C
	Headache (continued)	
14:30-15:20	Neurostimulation/modulation is as effective as pharmacotherapy for acute and preventive migraine treatment (can we confirm the usefulness of non-invasive neurostimulation for migraine treatment)	
	<i>Capsule:</i>	
	Moderator:	
	Introduction and Pre-Debate Voting	
	Yes: Miguel Lainez , Spain	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
15:20-15:50	Coffee Break, Exhibition & ePosters Visits	
	Headache (continued)	HALL C
15:50-16:40	Migraine pathophysiology begins several days before symptom onset, so treating during prodrome/aura is not an effective strategy	
	<i>Capsule:</i>	
	Moderator: Messoud Ashina , Denmark	
	Introduction and Pre-Debate Voting	
	Yes: Dimos D. Mitsikostas , Greece	
	No:	
	Discussion, Rebuttals and Post-Debate Voting	
16:40:17:30	Medication underuse headache	
	<i>Capsule:</i>	
	Moderator:	
	Introduction and Pre-Debate Voting	
	Yes: Wanakorn Rattanawong , Thailand	
	No: Dimos D. Mitsikostas , Greece	
	Discussion, Rebuttals and Post-Debate Voting	
17:40	Closing ceremony	